Open AccessPB2203 IMPROVEMENT OF THE HEMATOLOGIC TOXICITIES OF RUXOLITINIB IN PATIENTS WITH MPN‐ASSOCIATED MYELOFIBROSIS USING A COMBINATION OF THALIDOMIDE, STANOZOLOL AND PREDNISONE
Author(s) -
Duan M.,
zhou D.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000567292.55651.dd
Subject(s) - ruxolitinib , myelofibrosis , medicine , thalidomide , prednisone , tolerability , adverse effect , stanozolol , gastroenterology , international prognostic scoring system , anemia , surgery , myelodysplastic syndromes , bone marrow , anabolism , multiple myeloma
Background: Anemia and thrombocytopenia are the most frequently reported adverse events of ruxolitinib in patients with MPN‐associated myelofibrosis (MPN‐MF). Although thalidomide, androgens and prednisone have previously demonstrated improvements in myelofibrosis‐associated anemia, it is unclear whether these drugs are effective in patients taking ruxolitinib. Aims: To evaluate the efficacy and tolerability of combination therapy with low dose thalidomide, stanozolol and prednisone (TSP) in patients with IPSS intermediate‐2 or high‐risk myelofibrosis (MF) who received ruxolitinib treatment. Methods: Sixty‐five patients with MPN‐MF who took ruxolitinib were enrolled in this retrospective study, of which 46 patients also took TSP while 19 did not take TSP (TSP and non‐TSP groups). Results: Within the first 24 weeks, the proportion of patients with anemia and platelet count ≥50 × 10 9 /L were 45.7% and 67.4% in the TSP group as compared to 0% and 10.5% in the non‐TSP group (p < 0.001). The mean hemoglobin level in the non‐TSP group reached the nadir after approximately 12–16 weeks of therapy, but gradually increased in the TSP group. Summary/Conclusion: In summary, TSP regime can improve anemia and thrombocytopenia during ruxolitinib treatment in patients with MPN‐MF, and the associated adverse events were manageable.